XPD Regulates MIAT/miR-29a-3p/COL4A1 Axis to Impede Hepatocellular Carcinoma Development

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Xeroderma pigmentosum group D (XPD) is implicated in inhibiting hepatocellular carcinoma (HCC) cell growth.
• Understanding the molecular mechanisms of XPD in HCC is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the underlying mechanism of XPD in regulating hepatocellular carcinoma (HCC) progression.
• To investigate the role of the XPD/P53/MIAT/miR-29a-3p/COL4A1 axis in HCC metastasis and epithelial-mesenchymal transition (EMT).

Main Methods:

• Analysis of XPD, miR-29a-3p, MIAT, and COL4A1 expression in HCC tissues and cell lines.
• Overexpression and silencing experiments to assess the functional impact of XPD, MIAT, and COL4A1 on HCC cell behavior.
• Investigation of molecular interactions between XPD, P53, MIAT, and miR-29a-3p using co-immunoprecipitation and luciferase assays.
• In vivo studies using mouse models to evaluate the effect of XPD on tumor growth and metastasis.

Main Results:

• XPD and miR-29a-3p were downregulated, while MIAT and COL4A1 were upregulated in HCC.
• XPD overexpression suppressed HCC cell migration, invasion, and EMT, while MIAT or COL4A1 overexpression reversed these effects.
• MIAT promoted COL4A1 expression by sponging miR-29a-3p.
• XPD recruited P53 to repress MIAT expression, inhibiting HCC progression.
• In vivo, XPD upregulation reduced tumor growth and metastasis in mice.

Conclusions:

• XPD, through P53 recruitment, regulates the MIAT/miR-29a-3p/COL4A1 axis to inhibit HCC migration, invasion, EMT, and metastasis.
• XPD demonstrates potential as a therapeutic target for hepatocellular carcinoma (HCC) treatment.